Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation

Table 3

Posttransplant skin cancer by treatment group.

		Quasi Intention to Trea			Quasi Per Protoco
	All Patients	Everolimus Arm	MMF Arm		Remained on Everolimus	Other Immunosuppression
Skin Cancer, No.	(n=90)	(n=49)	(n=41)	P Valu	(n=18)	(n=72)	P Valu
Precancerous lesions or NMSC	34 (38)	18 (37)	16 (39)	.8	6 (33)	28 (39)	.6
Precancerous lesions	32 (36)	16 (33)	16 (39)	.5	5 (28)	27 (38)	.4
AK	18 (20)	9 (18)	9 (22)	.6	3 (17)	15 (21)	>.99
BD	12 (13)	8 (16)	4 (10)	.3	1 (6)	11 (15)	.45
AC	7 (8)	2 (4)	5 (12)	.24	1 (6)	6 (8)	>.99
NMSC	16 (18)	9 (18)	7 (17)	.8	1 (6)	15 (21)	.18
SCC	10 (11)	5 (10)	5 (12)	>.99	0 (0)	10 (14)	.20
BCC	9 (10)	6 (12)	3 (7)	.50	1 (6)	8 (11)	.68
Othe	3 (3)	2 (4)	1 (2)	>.99	0 (0)	3 (4)	>.99

MMF, mycophenolate mofetil; NMSC, nonmelanoma skin cancer; AK, actinic keratosis; BD, Bowen’s disease; AC, actinic cheilitis; SCC, squamous cell carcinoma of the skin; BCC, basal cell carcinoma.
Two superordinate groups, each with nine tests, Bonferroni correction (0.05/9 = 0.0056): P values < .0056 are deemed to be significant.
Patients stratified by original therapy arms from the previous interventional trial “Immunosuppressive therapy with Certican® (Everolimus) after lung transplantation”.
Comparing patients from the former everolimus arm, who remained on everolimus until dermatologic exam, to all other patients.
Percentages have been rounded to whole numbers and may not add up to 100.
Unless otherwise indicated, calculated using the Fisher exact test.
Calculated using the χ²-test.
Other entities found were acral lentiginous melanoma in situ (n=1), melanoma in situ (n=1), and cornu cutaneum (n=1).